HCV Protease

CAS No.	Product Name	Inquiry
1256388-51-8	Ledipasvir Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
1256751-11-7	Boceprevir-[d9] Boceprevir-[d9] is a stable isotopic labelled compound of Boceprevir. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
1258226-87-7	Ombitasvir Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 respectively.
1312547-19-5	Samatasvir Samatasvir is a potent HCV replication NS5A inhibitor that is effective and selective against infectious HCV and replicons with EC50s falling within a tight range of 2 to 24 pM for genotype 1-5 replicons.
1312608-46-0	Coblopasvir
1350462-55-3	MK-5172 hydrate In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
1365970-03-1	glecaprevir Glecaprevir is a suppressive agent of hepatitis C virus (HCV). Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM.
1422484-32-9	GSK2818713 GSK2818713 is a novel Hepatitis C NS5A replication complex inhibitor.
1425038-27-2	MK-5172 sodium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
1456607-71-8	Paritaprevir-dihydrate Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor).
1502654-87-6	Ledipasvir D-tartrate Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively). GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing.
1535212-07-7	Voxilaprevir Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity. Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively. Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research.
1606150-08-6	BMS-986144 BMS-986144, a third-generation, pan-genotype (GT) NS3/4A protease inhibitor, inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively.
1613591-70-0	N-[(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-4'-C-fluoro-2'-methyl-P-phenyl-5'-guanylyl]-L-alanine 1-methylethyl ester N-[(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-4'-C-fluoro-2'-methyl-P-phenyl-5'-guanylyl]-L-alanine 1-methylethyl ester is a nucleotide analog with modifications designed to enhance its antiviral properties. By mimicking natural nucleotides, this compound can integrate into viral RNA or DNA, disrupting replication due to its fluorinated and methylated groups, which increase stability and binding affinity. This makes it a potential candidate for inhibiting viral polymerases, thereby impeding viral replication and offering therapeutic benefits against various RNA or DNA viruses.
1620479-63-1	MK-6169
1966138-53-3	Coblopasvir-dihydrochloride Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection.
20831-76-9	Gentiopicroside Gentiopicroside is isolated from the roots of Gentiana manshurica Kitag.
2088243-03-0	NS5A-IN-4 NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC50 values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and gT5a.
208939-95-1	Hepatitis-Virus-C-NS3-Protease-Inhibitor-2 Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM.
208940-40-3	Ac-D-DGla-LI-Cha-C

※ Please kindly note that our services are for research use only.